Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dicel DM is an over-the-counter combination medication containing chlorpheniramine maleate, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride. It is indicated for the temporary relief of symptoms associated with the common cold, allergic rhinitis, and other upper respiratory infections, including nasal congestion, cough, and allergy symptoms like sneezing and itchy/watery eyes. Chlorpheniramine acts as an H1-receptor antagonist to reduce allergic responses. Dextromethorphan is an antitussive that acts on the cough center in the medulla to elevate the cough threshold. Pseudoephedrine is a sympathomimetic amine that acts as a nasal decongestant by vasoconstricting respiratory tract mucous membranes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dicel DM.